ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Behind the scenes: Primary immunodeficiencies in pediatric eosinophilic gastrointestinal diseases.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Behind the scenes: Primary immunodeficiencies in pediatric eosinophilic gastrointestinal diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary immunodeficiencies (PIDs) and eosinophilic gastrointestinal diseases (EGIDs) may share common underlying defects. However, no studies have investigated the frequency of PIDs among patients with EGIDs. In this study, we aimed to assess the frequency and spectrum of PIDs among our pediatric EGIDs patients.
methodPatients were prospectively evaluated over a two-year period. All patients were questioned according to ten warning signs of the Jeffrey Model Foundation. Routine laboratory tests and basic immunologic tests [serum immunoglobulin levels, isohemagglutinin titres, anti-HBs and anti-rubella Ig G titres] were performed on all participants. Advanced immunologic workup was performed in selected cases. All PID diagnoses were established according to the European Society for Immunodeficiencies' criteria. Electronic health records were screened for EGIDs' specific features, comorbidities, and previous laboratory tests.
resultsA total of 88 EGID patients [76% male, mean age: 12.02 years, 78 patients (88.6%) with EoE] were included. Fourteen patients were diagnosed with predominantly antibody deficiencies [unclassified antibody deficiency (n = 11), selective Ig A deficiency (n = 2), transient hypogammaglobulinemia of infancy (n = 1)]. Eighteen patients had abnormal Ig levels. Comparisons across the groups revealed no statistically significant differences in demographic, endoscopic, and pathologic features. Only topical swallowed budesonide unresponsiveness was significantly higher among cases with PID (p = .004).
conclusionPIDs may not be rare among patients with EGIDs. JMF's warning signs alone may be insufficient to identify affected patients in this population; therefore, additionally, basic immunologic tests as first step and advanced evaluation in suspected cases may be appropriate. Neither the key diagnostic endoscopic and pathological features nor the presence of strictures reliably distinguish PIDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.